Biotechnology News

NEW HAVEN, Conn., Aug. 09, 2021 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company...

Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social au 31 juillet 2021 (Article 223-16 du Règlement Général de l’Autorité des Marchés...

Monthly information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2021 (Article 223-16 of the General Regulations of the Autorité des...

– Recommended Phase 2 Dose of IGM-2323 Expected in 2021 – – Initial Data from Phase 1 Trial of IGM-8444 in Solid Cancers Expected in 2021 – – Expansion of IgM Platform into Infectious Diseases – ...

- SAD cohorts up to 640 mg and MAD cohorts up to 320 mg completed in extended Phase 1a trial of PLN-74809in healthy volunteers with no safety concerns identified- PLN-74809 Phase 2a 12-week trials in...

Announcing first solid tumor indication in HPV associated-malignancies – NEXI-003Advancing two lead product candidates in Phase 1/2 clinical trials Additional clinical and preclinical data anticipated...

Preclinical Data Support Initiation of Clinical Development of Lead GeneTAC Program for Friedreich Ataxia in the First Half of 2022 Leadership Team Strengthened with Appointment of Elizabeth Gordon,...

Imsidolimab GPP GEMINI-1 Phase 3 trial anticipated to initiate in Q3 2021 following recent FDA end-of-Phase 2 MeetingImsidolimab GALLOP GPP Phase 2 trial 16-week data to be orally presented at the...

On track to report initial VOR33 clinical data in the first half of 2022Announced collaborations with Abound Bio and Janssen to develop novel treatment systems for hematologic malignanciesInitiated...

GAITHERSBURG, Md., Aug. 09, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a...